Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmaceutica RemediaBSE:RMAH +3.75%60 EV-to-EBITDA is 3.22 as of Sep. 14, 2026, which is 6% below its 10-year median of 3.44. GuruFocus rates BSE:RMAH with a GF Score™ of 60/100 and a GF Value™ of lei0.79 (Fairly Valued). The stock has 11 warning signs investors should review. Among 100 Medical Distribution companies, Farmaceutica Remedia ranks better than 92% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Farmaceutica Remedia's enterprise value is lei41.3 Mil.
Farmaceutica Remedia's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was lei12.8 Mil. Therefore, Farmaceutica Remedia's EV-to-EBITDA for today is 3.22.
The historical rank and industry rank for Farmaceutica Remedia's EV-to-EBITDA or its related term are showing as below:
BSE:RMAH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.28 Med: 3.44 Max: 59.98
Current: 3.22
During the past 13 years, the highest EV-to-EBITDA of Farmaceutica Remedia was 59.98. The lowest was 0.28. And the median was 3.44.
BSE:RMAH's EV-to-EBITDA is ranked better than 92% of 100
companies
in the Medical Distribution industry
Industry Median: 8.61
vs BSE:RMAH: 3.22
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Farmaceutica Remedia's PE Ratio (TTM) for today is calculated as:
Farmaceutica Remedia's share price for today is lei0.83.
Farmaceutica Remedia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei0.037.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Farmaceutica Remedia's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSE:RMAH vs MCK, COR, CAH: EV-to-EBITDA Comparison
For the Medical Distribution subindustry, Farmaceutica Remedia's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's EV-to-EBITDA falls into.
Farmaceutica Remedia's current Enterprise Value is lei41.3 Mil.
Farmaceutica Remedia's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei12.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farmaceutica Remedia (BSE:RMAH) has a EV-to-EBITDA of 3.22 as of Sep. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Farmaceutica Remedia. This is near median its historical median of 3.44. Over the past decade, Farmaceutica Remedia's EV-to-EBITDA has ranged from 0.28 to 59.98. According to the industry distribution chart, Farmaceutica Remedia ranks #8 out of 100 companies in the Medical Distribution industry, placing it in the top 8%.
Is Farmaceutica Remedia's EV-to-EBITDA too high?
Farmaceutica Remedia's current EV-to-EBITDA of 3.22 is near median its 10-year median of 3.44. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 59.98. The Medical Distribution industry median EV-to-EBITDA is 8.61. Farmaceutica Remedia's value of 3.22 is 62.6% below this industry median. Based on the distribution chart, Farmaceutica Remedia ranks #8 out of 100 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Farmaceutica Remedia has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Farmaceutica Remedia ranks #8 out of 100 companies for EV-to-EBITDA. This places Farmaceutica Remedia in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 8.61. Farmaceutica Remedia's value of 3.22 is 62.6% below this benchmark. Historically, Farmaceutica Remedia's own EV-to-EBITDA has ranged from 0.28 to 59.98 over the past decade. While the company's 10-year median is 3.44 vs. the industry median of 8.61, Farmaceutica Remedia has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.61, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Farmaceutica Remedia's current EV-to-EBITDA of 3.22 is 62.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Farmaceutica Remedia. For the Medical Distribution industry, the median EV-to-EBITDA is 8.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmaceutica Remedia's current EV-to-EBITDA is 3.22, which is near median its own 10-year median of 3.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Based on GuruFocus' analysis, Farmaceutica Remedia (BSE:RMAH) is currently considered Fairly Valued. The stock's GF Value™ is lei0.79, compared to a current price of lei0.83 — trading 5.1% above its estimated fair value. The current EV-to-EBITDA is 3.22, which is near median its 10-year median of 3.44 and 62.6% below the Medical Distribution industry median of 8.61. Farmaceutica Remedia's overall GF Score™ is 60/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Farmaceutica Remedia (BSE:RMAH), the current EV-to-EBITDA is 3.22 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (BSE:RMAH) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.83 is trading 5.1% above its estimated GF Value™ of lei0.79.
GuruFocus considers Farmaceutica Remedia to be Fairly Valued.
Key valuation signals for BSE:RMAH:
EV-to-EBITDA: 3.22 (near median its 10-year median of 3.44)
GF Value™: lei0.79 vs. price of lei0.83 (5.1% above fair value)
Industry Position: 62.6% below the Medical Distribution median (#8 of 100)
No single metric tells the full story. See the BSE:RMAH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
60GF Score
Get the complete analysis for BSE:RMAH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:RMAH has been successfully added to your 
